pembrolizumabipilimumabnivolumabrelatlimabUniversity of Wisconsinadvanced stage melanomaunresectable stage III/IV melanoma
…uded: ipilimumab/nivolumab (8/16), nivolumab/relatlimab (7/16), pembrolizumab (1/16). ctDNA change from baseline to 3–4 weeks was not signifi…